193 related articles for article (PubMed ID: 32546271)
1. Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
Teng X; Wei L; Han L; Min D; Du Y
BMC Cancer; 2020 Jun; 20(1):562. PubMed ID: 32546271
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of expression level of CX3CL1-CX3CR1 axis in bone metastasis of lung cancer.
Liu Y; Ma H; Dong T; Yan Y; Sun L; Wang W
Clin Transl Oncol; 2021 Feb; 23(2):378-388. PubMed ID: 32638214
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
5. Study on diagnostic value of P1NP and β-CTX in bone metastasis of patients with breast cancer and the correlation between them.
Zuo CT; Yin DC; Fan HX; Lin M; Meng Z; Xin GW; Zhang YC; Cheng L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5277-5284. PubMed ID: 31298379
[TBL] [Abstract][Full Text] [Related]
6. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer.
Kong QQ; Sun TW; Dou QY; Li F; Tang Q; Pei FX; Tu CQ; Chen ZQ
Int J Biol Markers; 2007; 22(3):214-20. PubMed ID: 17922466
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
9. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
Bayrak SB; Ceylan E; Serter M; Karadağ F; Demir E; Çildağ O
Int J Clin Oncol; 2012 Apr; 17(2):112-8. PubMed ID: 21691728
[TBL] [Abstract][Full Text] [Related]
10. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Brown J; Rathbone E; Hinsley S; Gregory W; Gossiel F; Marshall H; Burkinshaw R; Shulver H; Thandar H; Bertelli G; Maccon K; Bowman A; Hanby A; Bell R; Cameron D; Coleman R
J Natl Cancer Inst; 2018 Aug; 110(8):871-879. PubMed ID: 29425304
[TBL] [Abstract][Full Text] [Related]
11. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of the levels of the bone turnover markers BAP and β-CTX with bone metastasis progress in lung cancer patients].
Tang Q; Zhao H; Jia R; Liu L
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):144-7. PubMed ID: 23514943
[TBL] [Abstract][Full Text] [Related]
13. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
14. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
15. Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.
Washam CL; Byrum SD; Leitzel K; Ali SM; Tackett AJ; Gaddy D; Sundermann SE; Lipton A; Suva LJ
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):972-83. PubMed ID: 23462923
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.
Chung JH; Park MS; Kim YS; Chang J; Kim JH; Kim SK; Kim SK
Yonsei Med J; 2005 Jun; 46(3):388-93. PubMed ID: 15988811
[TBL] [Abstract][Full Text] [Related]
17. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer.
Zhou Z; Chen ZW; Yang XH; Shen L; Ai XH; Lu S; Luo QQ
J Exp Clin Cancer Res; 2012 Apr; 31(1):34. PubMed ID: 22537906
[TBL] [Abstract][Full Text] [Related]
19. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
